Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

by Daniel Y.C. Heng, Ronald M. Bukowski
Published 2011-12-01

Renal cell carcinoma: evolving approaches to advanced non-clear cell carcinoma

by Daniel Y.C. Heng, Ronald M. Bukowski
Published 2011-12-01

High-risk bladder cancer: improving outcomes with perioperative chemotherapy

by Daniel Y.C. Heng, Jorge A. Garcia
Published 2011-12-01

High-risk bladder cancer: improving outcomes with perioperative chemotherapy

by Daniel Y.C. Heng, Jorge A. Garcia
Published 2011-12-01

Contemporary treatment of metastatic renal cell carcinoma

by Igor Stukalin, Nimira Alimohamed, Daniel Y.C. Heng
Published 2016-07-01

Cabozantinib in the treatment of advanced renal cell carcinoma: clinical trial evidence and experience

by Jose Manuel Ruiz-Morales, Daniel Y.C. Heng
Published 2016-12-01

Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions

by Daniel Y.C. Heng, Christian Kollmannsberger, Kim N. Chi
Published 2010-01-01

Review of the Interaction Between Body Composition and Clinical Outcomes in Metastatic Renal Cell Cancer Treated With Targeted Therapies

by Steven M Yip, Daniel Y. C. Heng, Patricia A. Tang
Published 2016-03-01

Corrigendum re “Impact of Body Mass Index on Survival Outcomes for Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis”...

by Kosuke Takemura, Satoru Yonekura, Laura E. Downey, Dimitris Evangelopoulos, Daniel Y.C. Heng
Published 2023-02-01

Impact of Body Mass Index on Survival Outcomes of Patients with Metastatic Renal Cell Carcinoma in the Immuno-oncology Era: A Systematic Review and Meta-analysis

by Kosuke Takemura, Satoru Yonekura, Laura E. Downey, Dimitris Evangelopoulos, Daniel Y.C. Heng
Published 2022-05-01

Imaging response to immune checkpoint inhibitors in patients with advanced melanoma: a retrospective observational cohort study

by Mehul Gupta, Mehul Gupta, Igor Stukalin, Igor Stukalin, Daniel E. Meyers, Daniel E. Meyers, Daniel Y. C. Heng, Daniel Y. C. Heng, Jose Monzon, Jose Monzon, Tina Cheng, Tina Cheng, Vishal Navani, Vishal Navani
Published 2024-05-01

Mutational signatures among young-onset testicular cancers

by Nicole E. Mealey, Dylan E. O’Sullivan, Cheryl E. Peters, Daniel Y. C. Heng, Darren R. Brenner
Published 2021-11-01

Efficacy and Safety of First-line Systemic Therapy for Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-analysis

by Nicholas A. Bosma, Matthew T. Warkentin, Chun Loo Gan, Safiya Karim, Daniel Y.C. Heng, Darren R. Brenner, Richard M. Lee-Ying
Published 2022-03-01

Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review

by Aly-Khan A. Lalani, Daniel Y. C. Heng, Naveen S. Basappa, Lori Wood, Nayyer Iqbal, Deanna McLeod, Denis Soulières, Christian Kollmannsberger
Published 2022-06-01

Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies

by Ellen Cusano, Chelsea Wong, Eddy Taguedong, Marcus Vaska, Tasnima Abedin, Nancy Nixon, Safiya Karim, Patricia Tang, Daniel Y. C. Heng, Doreen Ezeife
Published 2021-11-01

Effectiveness of Immune Checkpoint Inhibitor with Anti-PD-1 Monotherapy or in Combination with Ipilimumab in Younger versus Older Adults with Advanced Melanoma

by Taylor E. Woo, Igor Stukalin, Philip Q. Ding, Siddhartha Goutam, Michael Sander, Benjamin Ewanchuk, Winson Y. Cheung, Daniel Y. C. Heng, Tina Cheng
Published 2023-09-01

Evaluation of the modified immune prognostic index to prognosticate outcomes in metastatic uveal melanoma patients treated with immune checkpoint inhibitors

by Michael S. Sander, Igor Stukalin, Isabelle A. Vallerand, Siddhartha Goutam, Benjamin W. Ewanchuk, Daniel E. Meyers, Aliyah Pabani, Don G. Morris, Daniel Y. C. Heng, Tina Cheng
Published 2021-04-01

The Lung Immune Prognostic Index Discriminates Survival Outcomes in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors

by Daniel E. Meyers, Igor Stukalin, Isabelle A. Vallerand, Ryan T. Lewinson, Aleksi Suo, Michelle Dean, Scott North, Aliyah Pabani, Tina Cheng, Daniel Y.C. Heng, D. Gwyn Bebb, Don G. Morris
Published 2019-11-01

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio in Metastatic Testicular Cancer

by Domen Ribnikar, Igor Stukalin, Philippe L. Bedard, Robert J. Hamilton, Michael Jewett, Padraig Warde, Peter Chung, Lynn Anson-Cartwright, Arnoud J. Templeton, Eitan Amir, Aaron R. Hansen, Daniel Y. C. Heng, Jeremy Lewin
Published 2020-12-01

Effectiveness and Safety of First-Line Pembrolizumab in Older Adults with PD-L1 Positive Non-Small Cell Lung Cancer: A Retrospective Cohort Study of the Alberta Immunotherapy Datab...

by Heidi A. I. Grosjean, Samantha Dolter, Daniel E. Meyers, Philip Q. Ding, Igor Stukalin, Siddhartha Goutam, Shiying Kong, Quincy Chu, Daniel Y. C. Heng, D. Gwyn Bebb, Don G. Morris, Winson Y. Cheung, Aliyah Pabani
Published 2021-10-01